UCP2 upregulation promotes PLCγ-1 signaling during skin cell transformation
Annapoorna Sreedhar
Department of Pharmacology, Toxicology and Neuroscience, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana
Search for more papers by this authorJulia Lefort
Department of Pharmacology, Toxicology and Neuroscience, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana
Search for more papers by this authorPetra Petruska
Department of Pharmacology, Toxicology and Neuroscience, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana
Search for more papers by this authorXin Gu
Department of Pathology, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana
Search for more papers by this authorRunhua Shi
Feist-Weiller Cancer Center, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana
Search for more papers by this authorSumitra Miriyala
Department of Anatomy and Cell Biology, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana
Search for more papers by this authorManikandan Panchatcharam
Department of Anatomy and Cell Biology, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana
Search for more papers by this authorCorresponding Author
Yunfeng Zhao
Department of Pharmacology, Toxicology and Neuroscience, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana
Correspondence
Yunfeng Zhao, PhD, Department of Pharmacology, Toxicology and Neuroscience, LSU Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130-3932.
Email: [email protected]
Search for more papers by this authorAnnapoorna Sreedhar
Department of Pharmacology, Toxicology and Neuroscience, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana
Search for more papers by this authorJulia Lefort
Department of Pharmacology, Toxicology and Neuroscience, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana
Search for more papers by this authorPetra Petruska
Department of Pharmacology, Toxicology and Neuroscience, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana
Search for more papers by this authorXin Gu
Department of Pathology, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana
Search for more papers by this authorRunhua Shi
Feist-Weiller Cancer Center, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana
Search for more papers by this authorSumitra Miriyala
Department of Anatomy and Cell Biology, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana
Search for more papers by this authorManikandan Panchatcharam
Department of Anatomy and Cell Biology, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana
Search for more papers by this authorCorresponding Author
Yunfeng Zhao
Department of Pharmacology, Toxicology and Neuroscience, LSU Health Sciences Center in Shreveport, Shreveport, Louisiana
Correspondence
Yunfeng Zhao, PhD, Department of Pharmacology, Toxicology and Neuroscience, LSU Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130-3932.
Email: [email protected]
Search for more papers by this authorAbstract
Uncoupling protein 2 (UCP2), whose physiological role is to decrease mitochondrial membrane potential and reactive oxygen species (ROS) production, is often overexpressed in human cancers. UCP2 upregulation has recently been proposed as a novel survival mechanism for cancer cells. However, until now, how exactly UCP2 promotes tumorigenesis remains inconclusive. Based on a widely used skin cell transformation model, our data demonstrated that UCP2 differentially regulated ROS. UCP2 upregulation decreased superoxide whereas it increased hydrogen peroxide production with concomitant increase in the expression and activity of manganese superoxide dismutase (MnSOD), the primary mitochondrial antioxidant enzyme. Furthermore, hydrogen peroxide was responsible for induction of lipid peroxidation, and PLCγ-1 activation in UCP2 overexpressed cells. Additionally, PLCγ-1 activation enhanced skin cell transformation, and pharmacological, and siRNA mediated inhibition of PLCγ-1, markedly reduced colony formation, and 3D cell growth. Moreover, hydrogen peroxide scavenger, catalase, suppressed lipid peroxidation, and dampened PLCγ-1 activity. Taken together, our data suggest that (i) UCP2 is an important regulator of mitochondrial redox status and lipid signaling; (ii) hydrogen peroxide might mediate UCP2's tumor promoting activity; and (iii) pharmacological disruption of PLCγ-1 and/or hydrogen peroxide may have clinical utility for UCP2 overexpressed cancers.
REFERENCES
- 1 Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003; 552: 335–344.
- 2 Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014; 24: R453–R462.
- 3 Liou GY, Storz P. Reactive oxygen species in cancer. Free Radic Res. 2010; 44: 479–496.
- 4 Barrera G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol. 2012; 2012: 137289.
- 5 Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 2003; 17: 1195–1214.
- 6 Gago-Dominguez M, Jiang X, Castelao JE. Lipid peroxidation, oxidative stress genes and dietary factors in breast cancer protection: a hypothesis. Breast Cancer Res. 2007; 9: 1.
- 7 Cejas P, Casado E, Belda-Iniesta C, et al. Implications of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain). Cancer Causes Control. 2004; 15: 707–719.
- 8 Pizzimenti S, Toaldo C, Pettazzoni P, Dianzani MU, Barrera G. The “two-faced” effects of reactive oxygen species and the lipid peroxidation product 4-hydroxynonenal in the hallmarks of cancer. Cancers. 2010; 2: 338–363.
- 9 Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011; 11: 85–95.
- 10 Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 2004; 7: 97–110.
- 11 Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009; 8: 579–591.
- 12 Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell. 2006; 10: 175–176.
- 13 Robbins D, Zhao Y. New aspects of mitochondrial uncoupling proteins (UCPs) and their roles in tumorigenesis. Int J Mol Sci. 2011; 12: 5285–5293.
- 14 Baffy G. Uncoupling protein-2 and cancer. Mitochondrion. 2010; 10: 243–252.
- 15 Li W, Nichols K, Nathan CA, Zhao Y. Mitochondrial uncoupling protein 2 is up-regulated in human head and neck, skin, pancreatic, and prostate tumors. Cancer Biomark. 2013; 13: 377–383.
- 16 Krauss S, Zhang CY, Scorrano L, et al. Superoxide-mediated activation of uncoupling protein 2 causes pancreatic β cell dysfunction. J Clin Invest. 2003; 112: 1831–1842.
- 17 Mailloux RJ, Harper ME. Uncoupling proteins and the control of mitochondrial reactive oxygen species production. Free Radic Biol Med. 2011; 51: 1106–1115.
- 18 Dalla Pozza E, Fiorini C, Dando I, et al. Role of mitochondrial uncoupling protein 2 in cancer cell resistance to gemcitabine. Biochim Biophys Acta. 2012; 1823: 1856–1863.
- 19 Zhang J, Khvorostov I, Hong JS, et al. UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cells. EMBO J. 2011; 30: 4860–4873.
- 20 Vozza A, Parisi G, De Leonardis F, et al. UCP2 transports C4 metabolites out of mitochondria, regulating glucose and glutamine oxidation. Proc Natl Acad Sci USA. 2014; 111: 960–965.
- 21 Li W, Zhang C, Jackson K, et al. UCP2 knockout suppresses mouse skin carcinogenesis. Cancer Prev Res. 2015; 8: 487–491.
- 22 Claiborne A, Fridovich I. Purification of the o-dianisidine peroxidase from Escherichia coli B. Physicochemical characterization and analysis of its dual catalatic and peroxidatic activities. J Biol Chem. 1979; 254: 4245–4252.
- 23 Harwood HJ, Jr, Petras SF, Shelly LD, et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acidsynthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem. 2003; 278: 37099–37111.
- 24 Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. 2012; 48: 158–167.
- 25 Valle A, Oliver J, Roca P. Role of uncoupling proteins in cancer. Cancers. 2010; 2: 567–591.
- 26 Zhao Y, Chaiswing L, Velez JM, et al. P53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein—manganese superoxide dismutase. Cancer Res. 2005; 65: 3745–3750.
- 27 Bienert GP, Schjoerring JK, Jahn TP. Membrane transport of hydrogen peroxide. Biochim Biophys Acta. 2006; 1758: 994–1003.
- 28 Wong-Ekkabut J, Xu Z, Triampo W, Tang IM, Tieleman DP, Monticelli L. Effect of lipid peroxidation on the properties of lipid bilayers: a molecular dynamics study. Biophys J. 2007; 93: 4225–4236.
- 29 Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longevity. 2014; 2014: 360438.
- 30 Sala G, Dituri F, Raimondi C, et al. Phospholipase Cγ1 is required for metastasis development and progression. Cancer Res. 2008; 68: 10187–10196.
- 31 Park JB, Lee CS, Jang JH, et al. Phospholipase signaling networks in cancer. Nat Rev Cancer. 2012; 12: 782–792.
- 32 Suh PG, Park JI, Manzoli L, et al. Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep. 2008; 41: 415–434. Review.
- 33 Park JG, Lee YH, Kim SS, et al. Overexpression of phospholipase C-γ1 in familial adenomatous polyposis. Cancer Res. 1994; 54: 2240–2244.
- 34 Nomoto K, Tomita N, Miyake M, Xhu DB, Logerfo PR, Weinstein IB. Expression of phospholipases γ1, β1, and δ1 in primary human colon carcinomas and colon carcinoma cell lines. Mol Carcinog. 1995; 12: 146–152.
- 35
Noh DY,
Lee YH,
Kim SS, et al. Elevated content of phospholipase C-γ1 in colorectal cancer tissues.
Cancer.
1994;
73: 36–41.
10.1002/1097-0142(19940101)73:1<36::AID-CNCR2820730108>3.0.CO;2-5 CAS PubMed Web of Science® Google Scholar
- 36 Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006; 24: 2666–2672.
- 37 Nanney LB, Gates RE, Todderud G, King LE, Jr, Carpenter G. Altered distribution of phospholipase C-gamma 1 in benign hyperproliferative epidermal diseases. Cell Growth Differ. 1992; 3: 233–239.
- 38 Lisanti MP, Martinez-Outschoorn UE, Lin Z, et al. Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: the seed and soil also needs “fertilizer”. ABBV Cell Cycle. 2011; 10: 2440–2449.
- 39 López-Lázaro M. Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. Cancer Lett. 2007; 252: 1–8.
- 40 Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991; 51: 794–798.
- 41 Preston TJ, Muller WJ, Singh G. Scavenging of extracellular H2O2 by catalase inhibits the proliferation of HER-2/Neu-transformed rat-1 fibroblasts through the induction of a stress response. J Biol Chem. 2001; 276: 9558–9564.
- 42 Wang XT, McCullough KD, Wang XJ, Carpenter G, Holbrook NJ. Oxidative stress-induced phospholipase C-γ1 activation enhances cell survival. J Biol Chem. 2001; 276: 28364–28371.
- 43 Yuan W, Guo J, Li X, et al. Hydrogen peroxide induces the activation of the phospholipase C-γ1 survival pathway in PC12 cells: protective role in apoptosis. Acta Biochim Biophys Sin. 2009; 41: 625–630.
- 44 Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012; 21: 297–308.
- 45 Warburg O. On the origin of cancer cells. Science. 1956; 123: 309–314.
- 46 Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324: 1029–1033.
- 47 Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004; 4: 891–899.
- 48 Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006; 66: 8927–8930.
- 49 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–674.
- 50 Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016; 41: 211–218.
- 51 Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer. 2013; 13: 227–232.
- 52 Samudio I, Harmancey R, Fiegl M, et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest. 2010; 120: 142–156.
- 53 Phan LM, Yeung S-CJ, Lee M-H. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med. 2014; 11: 1–19.
- 54 Currie E, Schulze A, Zechner R, Walther TC, Farese RV. Cellular fatty acid metabolism and cancer. Cell Metab. 2013; 18: 153–161.
- 55 Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010; 35: 427–433.
- 56 DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 2007; 104: 19345–19350.
- 57 DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008; 7: 11–20.
- 58 Boland ML, Chourasia AH, Macleod KF. Mitochondrial dysfunction in cancer. Front Oncol. 2013; 3: 292.
- 59 Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015; 34: 111.
- 60 Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009; 417: 1–3.
- 61 Buettner GR. Superoxide dismutase in redox biology: the roles of superoxide and hydrogen peroxide. Anticancer Agents Med Chem. 2011; 11: 341–346.
- 62 Imlay JA. Cellular defenses against superoxide and hydrogen peroxide. Annu Rev Biochem. 2008; 77: 755–776.
- 63 van der Vliet A, Janssen-Heininger YM. Hydrogen peroxide as a damage signal in tissue injury and inflammation: murderer, mediator, or messenger? J Cell Biochem. 2014; 115: 427–435.
- 64 Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis. 2000; 5: 415–418.
- 65 Wang J, Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther. 2008; 7: 1875–1884.
- 66 Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog. 2006; 5: 14.
- 67 Van Remmen H, Ikeno Y, Hamilton M, et al. Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiol Genomics. 2003; 16: 29–37.
- 68 Sarsour EH, Kalen AL, Goswami PC. Manganese superoxide dismutase regulates a redox cycle within the cell cycle. Antioxid Redox Signal. 2014; 20: 1618–1627.
- 69 Kinnula VL, Crapo JD. Superoxide dismutases in malignant cells and human tumors. Free Radic Biol Med. 2004; 36: 718–744.
- 70 Alexandre J, Batteux F, Nicco C, et al. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer. 2006; 119: 41–48.
- 71 Afanas'ev I. Reactive oxygen species signaling in cancer: comparison with aging. Aging Dis. 2011; 2: 219.
- 72 Zhao Y, Xue Y, Oberley TD, et al. Overexpression of manganese superoxide dismutase suppresses tumor formation by modulation of activator protein-1 signaling in a multistage skin carcinogenesis model. Cancer Res. 2001; 61: 6082–6088.
- 73 Hirose KU, Longo DL, Oppenheim JJ, Matsushima K. Overexpression of mitochondrial manganese superoxide dismutase promotes the survival of tumor cells exposed to interleukin-1, tumor necrosis factor, selected anticancer drugs, and ionizing radiation. FASEB J. 1993; 7: 361–368.
- 74 Kim AK. Modulation of MnSOD in cancer: epidemiological and experimental evidences. Toxicol Res. 2010; 26: 83–93.
- 75 Candas D, Li JJ. MnSOD in oxidative stress response-potential regulation via mitochondrial protein influx. Antioxid Redox Signal. 2014; 20: 1599–1617.
- 76 Williams MD, Van Remmen H, Conrad CC, Huang TT, Epstein CJ, Richardson A. Increased oxidative damage is correlated to altered mitochondrial function in heterozygous manganese superoxide dismutase knockout mice. J Biol Chem. 1998; 273: 28510–28515.
- 77 Duttaroy A, Paul A, Kundu M, Belton A. A Sod2 null mutation confers severely reduced adult life span in Drosophila. Genetics. 2003; 165: 2295–2299.
- 78 Hart PC, Mao M, De Abreu AL, et al. MnSOD upregulation sustains the Warburg effect via mitochondrial ROS and AMPK-dependent signalling in cancer. Nat Commun. 2015; 6: 6053.
- 79 Vilema-Enríquez G, Arroyo A, Grijalva M, Amador-Zafra RI, Camacho J. Molecular and cellular effects of hydrogen peroxide on human lung cancer cells: potential therapeutic implications. Oxid Med Cell Longevity. 2016; 2016: 1908164.